Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Lunch and Poster Display session

35P - Genomic and clinical landscape of metastatic hormone receptor-positive breast cancers carrying ESR1 alterations

Date

16 May 2024

Session

Lunch and Poster Display session

Presenters

Luca Boscolo Bielo

Citation

Annals of Oncology (2024) 9 (suppl_4): 1-34. 10.1016/esmoop/esmoop103010

Authors

L. Boscolo Bielo1, E. Guerini Rocco2, D. Trapani3, P. Zagami4, B. Taurelli Salimbeni4, A. Esposito3, K. Venetis4, N. Fusco5, C. Criscitiello4, A. Marra5, G. Curigliano4

Author affiliations

  • 1 Università degli Studi di Milano, Milan/IT
  • 2 IEO - Istituto Europeo di Oncologia IRCCS, 20141 - Milan/IT
  • 3 European Institute of Oncology IRCCS, 20141 - Milan/IT
  • 4 IEO - Istituto Europeo di Oncologia IRCCS, Milan/IT
  • 5 European Institute of Oncology IRCCS, Milan/IT

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 35P

Background

Genomic alterations in ESR1 are enriched in endocrine therapy (ET)-resistant, estrogen receptor-positive (ER+) metastatic breast cancer (mBC). In the present analysis, we investigated clinical and genomic differences among ESR1 wild type (ESR1 WT ) and ESR1-mutated (ESR1 MUT ) ER+ mBCs.

Methods

Clinical and genomic data was retrieved from cBioPortal using the MSK MetTropism dataset. Metastatic, post-ET ER+/HER2- tumor samples were included in the analysis. Oncogenic and likely oncogenic alterations according to OncoKB were included in the analysis. False discovery rate (FDR) correction was applied for multiple hypothesis testing.

Results

Among 707 ER+/HER2- mBCs, 136 ESR1 MUT in 131 tumors were found, of whom 85.29% (116/136) consisted in alterations located in helices 11 and 12 (H11-12), 10.29% (14/136) in H5 (E380X), and 4.41% (6/136) in other domains of the ESR1 gene. The frequency of ESR1 MUT was higher in ductal vs. lobular mBC (20.1% vs. 13.2%; P=0.04) and enriched in liver metastasis compared to other sites (22.5% vs. 12.7%; q=0.02). ESR1 MUT tumors showed higher fraction of genome altered (FGA) (0.28 [IQR 0.15 0.43] vs. 0.22 [0.11-0.38]; P=0.04) and tumor mutational burden (TMB) (4.89 [IQR 3.46-6.85] vs. 3.92 [2.59-6.05] mut/Mb; P=0.001) compared to ESR1 WT mBC. Tumors harboring E380X alterations had higher TMB compared to those with H11-12 alterations (8.24 [IQR 5.06-15.3] vs. 4.89 [3.46-6.75] mut/Mb; P=0.01). In both ESR1 MUT and ESR1 WT tumors, PIK3CA represented the most common altered gene (38% and 42%). TP53 gene alterations were enriched in ESR1 WT tumors (36% vs. 14%) (Odd Ratio (OR) 3.17, 95% CI 1.88-5.64, q=0.001). Considering signaling pathways, ESR1 MUT tumors showed a lower occurrence of TP53-pathway (OR 0.48, 95%CI 0.30-0.74; q=0.003) and MAPK (OR 0.29, 95%CI 0.11-0.65; q=0.009) alterations. TP53 (q<0.001), CDH1 (q<0.001) and ERBB2 (q<0.001) demonstrated mutual exclusivity with ESR1 MUT .

Conclusions

ER+/HER2- mBCs carrying ESR1MUT exhibit a divergent genomic background, such as a low number of TP53 and MAPK pathway alterations. Less common ESR1 alterations falling outside the H11-H12 region seem to occur in tumors with high TMB, deserving further investigation to understand their real actionability.

Legal entity responsible for the study

L. Boscolo Bielo.

Funding

Has not received any funding.

Disclosure

C. Criscitiello: Financial Interests, Personal, Invited Speaker: Pfizer, Novartis, Eli Lilly, Roche, Gilead; Financial Interests, Personal, Advisory Board: MSD, Seagen, AstraZeneca, Daiichi Sankyo. A. Marra: Financial Interests, Personal, Advisory Board: Menarini/Stemline; Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Other, Travel Support: AstraZeneca. G. Curigliano: Financial Interests, Personal, Invited Speaker: Roche, AstraZeneca, Daiichi Sankyo, Novartis, Pfizer, Pfizer; Financial Interests, Personal, Advisory Board: Roche, AstraZeneca, Daiichi Sankyo, Lilly, Pfizer, Veracyte, BMS, Merck, Exact Sciences, Celcuity; Financial Interests, Personal, Advisory Board, Advisory Board: Menarini, Gilead; Financial Interests, Personal, Other, Advisory Board: Ellipsis; Financial Interests, Institutional, Research Grant, Investigator Initiated Trial: Merck; Financial Interests, Institutional, Funding, Phase I studies: BMS, Novartis, AstraZeneca, Daiichi Sankyo, Roche, Blueprint Medicine, Kymab, Astellas, Sanofi, Philogen; Financial Interests, Institutional, Invited Speaker, Phase I clinical basket trial: Relay Therapeutics; Non-Financial Interests, Officer, Italian National Health Council as Advisor for Ministry of Health: Consiglio Superiore di Sanità; Non-Financial Interests, Advisory Role, Member of the Scientific Council. Patient advocacy association: Europa Donna; Non-Financial Interests, Advisory Role, Cancer Research Foundation: Fondazione Beretta; Non-Financial Interests, Member of Board of Directors, No compensation for this role. This a public national company for cancer prevention: Lega Italiana Lotta ai Tumori; Non-Financial Interests, Officer, Member of the Advisory Council: EUSOMA; Non-Financial Interests, Officer, ESMO Clinical Practice Guidelines Chair: ESMO; Non-Financial Interests, Member of Board of Directors, Chair of Clinical Practice Guidelines Committee: ESMO. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.